Guangdong Zhongsheng Ruichuang Pharmaceutical Co. Ltd. has described glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of type 2 diabetes, obesity, atherosclerosis, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH), hyperglycemia, cerebral infarction, hypertension and Parkinson’s disease.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have divulged bifunctional epoxide hydrolase 2 (EPHX2; sEH) inhibitors reported to be useful for the treatment of pain, diabetic retinopathy and neurodegeneration. An exemplified compound (Ex 23 pg 78, claim 18) inhibited human sEH activity (IC50=0.5 nM) using Rapidfire mass spectrometry (RFMS) assays (WO 2025125135).
Latvian Institute of Organic Synthesis has identified subtilisin-like protease 1 (PfSUB1) (Plasmodium falciparum) inhibitors reported to be useful for the treatment of malaria.
Idorsia Pharmaceuticals Ltd. has synthesized aryl sulfone and sulfanone derivatives acting as orexin OX2 receptor agonists reported to be useful for the treatment of eating disorders, fatigue, Kleine-Levin syndrome, narcolepsy, obesity, pain, and psychiatric and inflammatory disorders, among others.
Eli Lilly & Co. and Evotec International GmbH have disclosed Rho-associated protein kinase 2 (ROCK2) inhibitors reported to be useful for the treatment of cancer, autoimmune disease, fibrosis, and inflammatory and neurological disorders.
Acurex Biosciences Corp. has divulged fused quinone compounds acting as ferroptosis inhibitors reported to be useful for the treatment of mitochondrial disease.
Deciphera Pharmaceuticals LLC has identified phosphatidylinositol 3-kinase catalytic subunit type 3 (PIK3C3; Vps34) inhibitors reported to be useful for the treatment of cancer.
Alterome Therapeutics Inc. has synthesized RAC-α serine/threonine-protein kinase (AKT1; PKB α) (E17K mutant) inhibitors reported to be useful for the treatment of cancer.
RSS
